|Description:||Rabbit polyclonal antibody to COL4A1.|
|Dilutions:||WB: 1:200 - 1:500.|
|Immunogen:||A synthetic peptide of human COL4A1.|
|Formulation:||Supplied in Phosphate Buffered Saline, pH 7.30, with 0.02% Sodium Azide and 50% Glycerol.|
|Storage:||Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.|
|Function:||Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.|
|Tissue Specificity:||Highly expressed in placenta.|
|Involvement in Disease:||Brain small vessel disease with or without ocular anomalies: An autosomal dominant disease characterized by weakening of the blood vessels in the brain and retinal arteriolar tortuosity. In affected individuals, stroke is often the first symptom and is usually caused by bleeding in the brain (hemorrhagic stroke) rather than a lack of blood flow in the brain (ischemic stroke). Patients also have leukoencephalopathy and may experience seizures and migraine headaches accompanied by visual sensations known as auras.
Hereditary angiopathy with nephropathy aneurysms and muscle cramps: The clinical renal manifestations include hematuria and bilateral large cysts. Histologic analysis revealed complex basement membrane defects in kidney and skin. The systemic angiopathy appears to affect both small vessels and large arteries.
Porencephaly 1: A neurologic disorder characterized by a fluid-filled cysts or cavities within the cerebral hemispheres, neurologic manifestations, facial paresis, and visual defects. Affected individuals typically have hemiplegia, seizures, and intellectual disability. Porencephaly type 1 is usually unilateral and results from focal destructive lesions such as fetal vascular occlusion or birth trauma.
Intracerebral hemorrhage: A pathological condition characterized by bleeding into one or both cerebral hemispheres including the basal ganglia and the cerebral cortex. It is often associated with hypertension and craniocerebral trauma. Intracerebral bleeding is a common cause of stroke.
Tortuosity of retinal arteries: A disease characterized by marked tortuosity of second- and third-order retinal arteries with normal first-order arteries and venous system. Most patients manifest variable degrees of symptomatic transient vision loss due to retinal hemorrhage following minor stress or trauma.
Schizencephaly: Extremely rare human congenital disorder characterized by a full-thickness cleft within the cerebral hemispheres. These clefts are lined with gray matter and most commonly involve the parasylvian regions. Large portions of the cerebral hemispheres may be absent and replaced by cerebro-spinal fluid.
|Sequence Similarities:||Belongs to the type IV collagen family.|
|Post-Translational Modification:||Lysines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in all cases and bind carbohydrates.|
|Cellular Location:||Secreted > Extracellular space > Extracellular matrix > Basement membrane.|
|Synonyms:||Alpha-1 type I collagen Antibody
COL4A1 NC1 domain Antibody
Collagen alpha 1 chain Antibody
Collagen alpha 1(I) chain Antibody
Collagen alpha 1(II) chain Antibody
Collagen alpha 1(III) chain Antibody
Collagen alpha 1(IV) chain Antibody
Collagen alpha 1(V) chain Antibody
Collagen alpha-1(I) chain Antibody
collagen alpha-1(IV) chain Antibody
Collagen I + II + III + IV + V Antibody
Collagen I alpha 1 polypeptide Antibody
Collagen II alpha 1 polypeptide Antibody
Collagen IV Antibody
Collagen IV Alpha 1 Polypeptide Antibody
Collagen IV Alpha 2 Polypeptide Antibody
Collagen Of Basement Membrane Alpha 1 Chain Antibody
Collagen Of Basement Membrane Alpha 2 Chain Antibody
Collagen type I alpha 1 Antibody
Collagen type II alpha 1 Antibody
Collagen type III alpha 1 Antibody
Collagen Type IV Antibody
Collagen Type IV Alpha 1 Antibody
Collagen Type IV Alpha 2 Antibody
Collagen Type IV Alpha 3 Antibody
Collagen Type IV Alpha 4 Antibody
Collagen Type IV Alpha 5 Antibody
Collagen type V alpha 1 Antibody
|Information:||Target information shown above is from the UniProt Consortium.|